Tolerability outcomes of NVC 422 administered as a bladder and catheter lavage solution in volunteers
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2011
At a glance
- Drugs Auriclosene (Primary)
- Indications Bacterial infections; Catheter infections; Urinary tract infections
- Focus Adverse reactions
- Sponsors NovaBay Pharmaceuticals
- 02 Feb 2011 Planned number of patients changed to 32, according to a media release from NovaBay Pharmaceuticals.
- 14 May 2008 Status changed from in progress to completed, according to a NovaBay media release.
- 13 May 2008 Results have been presented in a media release by NovaBay Pharmaceuticals.